Upcoming Milestones, Key Investment Points for Bio Blast Pharma (ORPN) Being Missed by Investors - Roth Capital
Tweet Send to a Friend
Roth Capital affirms Bio Blast Pharma (Nasdaq: ORPN) at Buy wth a price target of $18 following recent conversations with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
